Histogenics
Waltham, Massachusetts, United States
About Histogenics
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $226.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2018)
- Ticker: nasdaq:HSGX
- Website: histogenics.com
- Phone: (781) 547-4452
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/histogenics-2204872 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.